Sean Laaman
Stock Analyst at Morgan Stanley
(3.91)
# 522
Out of 5,152 analysts
26
Total ratings
61.9%
Success rate
9.64%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EIKN Eikon Therapeutics | Initiates: Overweight | $32 | $14.04 | +127.92% | 1 | Mar 2, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $96 → $98 | $64.99 | +50.79% | 2 | Feb 25, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $48 → $49 | $40.97 | +19.60% | 6 | Feb 2, 2026 | |
| AXSM Axsome Therapeutics | Downgrades: Equal-Weight | $196 → $204 | $161.66 | +26.19% | 4 | Jan 8, 2026 | |
| CERT Certara | Maintains: Equal-Weight | $16 → $12 | $6.95 | +72.66% | 2 | Dec 18, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Overweight | $20 | $10.22 | +95.69% | 1 | Dec 5, 2025 | |
| MPLT MapLight Therapeutics | Initiates: Overweight | $34 | $18.29 | +85.89% | 1 | Nov 21, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $90 → $115 | $61.00 | +88.52% | 3 | Oct 30, 2025 | |
| RMD ResMed | Maintains: Overweight | $298 → $304 | $251.60 | +20.83% | 2 | Oct 21, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $350 → $383 | $300.75 | +27.35% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $3 → $1.5 | $2.00 | -25.00% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $67 | $67.59 | -0.87% | 1 | Feb 14, 2025 |
Eikon Therapeutics
Mar 2, 2026
Initiates: Overweight
Price Target: $32
Current: $14.04
Upside: +127.92%
BridgeBio Pharma
Feb 25, 2026
Maintains: Overweight
Price Target: $96 → $98
Current: $64.99
Upside: +50.79%
Exelixis
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $48 → $49
Current: $40.97
Upside: +19.60%
Axsome Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $196 → $204
Current: $161.66
Upside: +26.19%
Certara
Dec 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $12
Current: $6.95
Upside: +72.66%
BridgeBio Oncology Therapeutics
Dec 5, 2025
Initiates: Overweight
Price Target: $20
Current: $10.22
Upside: +95.69%
MapLight Therapeutics
Nov 21, 2025
Initiates: Overweight
Price Target: $34
Current: $18.29
Upside: +85.89%
Disc Medicine
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $115
Current: $61.00
Upside: +88.52%
ResMed
Oct 21, 2025
Maintains: Overweight
Price Target: $298 → $304
Current: $251.60
Upside: +20.83%
BeOne Medicines AG
Oct 20, 2025
Maintains: Overweight
Price Target: $350 → $383
Current: $300.75
Upside: +27.35%
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $2.00
Upside: -25.00%
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $67.59
Upside: -0.87%